In combination, class 1a, 1b and 2a peptides can thus be informative in identifying and distinguishing different splice isoforms. Because a substantial part of the continuous updates to eukaryotic ...
GemVax revealed Tuesday that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy (PSP). PSP is a degenerative disease, not unlike Parkinson’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback